Imbruvica plus venetoclax significantly extends PFS in untreated CLL patients compared to chlorambucil plus Gazyva, with 52 months versus 31 months. The combination therapy shows durable efficacy and ...

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved progression-free survival in chronic lymphocytic leukemia (CLL) compared with ...

Please provide your email address to receive an email when new articles are posted on . Combination ibrutinib and venetoclax remains effective as first-line CLL treatment. Researchers reported 5-year ...

Please provide your email address to receive an email when new articles are posted on . Fixed-duration pirtobrutinib plus venetoclax with or without rituximab was well-tolerated in relapsed or ...

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma Modulates Intratumoral CD4/CD8 Ratio and Tumor Microenvironment: A Multicenter Phase II Clinical Trial ...

“Patients treated with the venetoclax-obinutuzumab combination showed a statistically significant sustained prolongation of PFS compared with patients treated with chlorambucil-obinutuzumab (76.2 vs ...

Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic lymphocytic leukemia, according to an analysis. A recent study highlights the ...